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Abstract
Aberrant left-right patterning in the developing human embryo can lead to a broad spectrum of congenital malformations. The
causes of most laterality defects are not known, with variants in established genes accounting for <20% of cases. We sought to
characterize the genetic spectrum of these conditions by performing whole-exome sequencing of 323 unrelated laterality
cases. We investigated the role of rare, predicted-damaging variation in 1726 putative laterality candidate genes derived from
model organisms, pathway analyses, and human phenotypes. We also evaluated the contribution of homo/hemizygous exon
deletions and gene-based burden of rare variation. A total of 28 candidate variants (26 rare predicted-damaging variants and 2
hemizygous deletions) were identified, including variants in genes known to cause heterotaxy and primary ciliary dyskinesia
(ACVR2B, NODAL, ZIC3, DNAI1, DNAH5, HYDIN, MMP21), and genes without a human phenotype association, but with
prior evidence for a role in embryonic laterality or cardiac development. Sanger validation of the latter variants in probands
and their parents revealed no de novo variants, but apparent transmitted heterozygous (ROCK2, ISL1, SMAD2), and
hemizygous (RAI2, RIPPLY1) variant patterns. Collectively, these variants account for 7.1% of our study subjects. We also
observe evidence for an excess burden of rare, predicted loss-of-function variation in PXDNL and BMS1- two genes relevant
to the broader laterality phenotype. These findings highlight potential new genes in the development of laterality defects, and
suggest extensive locus heterogeneity and complex genetic models in this class of birth defects.
Introduction
In humans, the normal patterning of internal organs on the
left or right side of the body is a complex, yet highly
orchestrated, developmental process. Consequently,
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disordered left-right (LR) patterning can lead to a broad
spectrum of laterality defects, including situs inversus
totalis (SIT), in which there is complete transposition of
visceral organs with maintenance of organ concordance,
and heterotaxy (HTX) in which at least one organ is dis-
cordant along the left-right axis [1]. SIT is rarely associated
with congenital organ malformations, whereas heterotaxy is
highly associated with a host of congenital malformations
that include isomerisms (in which normally asymmetric
structures appear duplicated on both left and right e.g.,
bilateral bilobed lung), segmental reversals of sidedness
(e.g., dextrocardia), and failures of embryonic structures to
regress (e.g., persistent left superior vena cava) or complete
loss of structures (e.g., asplenia). The conventional ana-
tomic classification of HTX has been based on splenic and
atrial/bronchial situs—namely asplenia-type/right atrial
isomerism and polysplenia-type/left atrial isomerism.
Although there are characteristic lesions within each of
these classifications, their considerable anatomic and
mechanistic overlap justifies their combination in epide-
miological and genetic studies [2].
Heart formation in the early embryo requires proper LR
axis signaling [3], and therefore, it is not surprising that
cardiovascular malformations occur in approximately 80%
of individuals with heterotaxy. The resulting spectrum of
lesions is extensive and includes anomalies of pulmonary
and systemic venous return, atrioventricular septal defects,
ventricular inversion, and hypoplasia, transposition of the
great arteries (TGA), double outlet right ventricle (DORV),
and heart rhythm disorders [4]. In fact, abnormal LR pat-
terning may contribute to as much as 3–7% of all congenital
heart defects, and, with the associated multi-organ invol-
vement, the medical and surgical management of such cases
is particularly challenging [5]. The mortality for HTX thus
remains appreciably high [6].
The etiologies of congenital laterality defects are com-
plex and thought to include both environmental and genetic
factors. Contributing environmental factors are poorly
understood, but have been consistently observed [7]. From a
genetic standpoint, laterality defects are occasionally
observed in patients with chromosome abnormalities and
genomic disorders [6, 8], and rare families have been
reported with apparent segregation of HTX or related heart
defects as autosomal dominant, autosomal recessive or X-
linked traits [9–12]. There is thus some support for highly-
penetrant rare variants, i.e., monogenic or Mendelian
inheritance, causing laterality defects. At the same time, it
has been noted that the same gene can cause the divergent
phenotypes of SIT and HTX, and that polysplenia- or
asplenia-types of HTX can be observed in families segre-
gating the same pathogenic allele in the same disease gene,
as well as in isolated cases with distinct alleles in the same
gene [9, 10, 13]. In this context, the complexity of the heart
defects and associated birth defects observed among
patients with presumed protein-damaging variants in ZIC3
and CFC1 is most illustrative; there is little genotype-
phenotype correlation among patients with ZIC3 variants,
and the spectrum of heart defects is extensive, including
defects not traditionally associated with laterality pheno-
types and complex extra-cardiac malformations [10, 13].
Similarly, CFC1 variants have been associated with a
variety of isolated congenital heart defects in addition to
laterality abnormalities [9]. These observations demonstrate
that there is substantial overlap in the genetic etiology of
congenital heart defects, regardless of their phenotypic
classification.
The known genes contributing to laterality defects
account for only 15–20% of cases, and are largely asso-
ciated with NODAL/TGFβ signaling (NODAL, CFC1,
ACVR2B, LEFTYB, GDF1, TGFBR2, FOXH1), SHH sig-
naling (ZIC3, LZTFL1) and monocilia functions (NPHP2,
NPHP3, NPHP4, PKD2, TTC8) (see Supplementary
Table S1). This connection to ciliary function is further
reinforced by the observation that ~50% of patients with
primary ciliary dyskinesia (PCD) defects have SIT and
~10% present with heterotaxy [8, 14]. Other gene variants
with well-studied connections to early cardiac development
(NKX2-5, CRELD1, MMP21, PKD1L1) and genes with
relatively limited functional annotation (BCL9L,
SHROOM3,MEGF8) have also been implicated in laterality
defects. A critical review of these reports demonstrates that,
although significant recurrence in first-degree relatives [15]
and increased frequency in consanguineous populations
[16] support a single gene view of laterality defects, puta-
tive pathogenic variants are often transmitted from unaf-
fected parents, suggesting additional factors affect disease
penetrance. Thus, these primary epidemiological observa-
tions are compatible with both Mendelian and oligogenic or
complex inheritance mechanisms.
To explore the role of genetic variation in laterality
defects, we performed singleton whole-exome sequencing
(WES) of 323 unrelated cases, and investigated rare
predicted-damaging variation, homo/hemizygous exon
deletions, and gene-based burden of rare variation in a set of
biologically-implicated cardiovascular genes defined a
priori.
Results
High-quality candidate variants identified in the laterality
cohort (Methods) were prioritized using three criteria: (1)
extremely low allele frequency compared to population-
based databases (minor allele <0.05% in ARIC, 1000
Genomes Project, ESP, ExAC, gnomAD—see Methods),
(2) prediction of a deleterious functional effect including
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loss-of-function (LOF – e.g., frameshift-, stopgain-, and
splice site- variants within 2 base pairs of intron-exon
boundaries) or damaging nonsynonymous variation
(Methods), and (3) a priori evidence for the gene playing a
role in laterality or cardiac development (Methods; Sup-
plementary Table S3). A total of 24 single nucleotide var-
iants (SNVs) or small insertions/deletions met these criteria,
representing 15 distinct genes (Table 1). The cases carrying
these candidate SNVs represented ~7% of our total laterality
cohort. Of these genes, nine have been previously impli-
cated in human laterality disorders, and six represent novel
candidate genes. We further investigated the clinical pre-
sentation of variant-carrying patients as well as their asso-
ciated inheritance patterns.
Known laterality genes
Six cases had rare LOF or nonsynonymous damaging SNVs
in two known dominant laterality genes—NODAL and
ACVR2B. The p.(R383C) missense variant observed in
ACVR2B was inherited from an affected parent, and further
analysis of this pedigree demonstrated clear segregation of
the variant with five affected individuals from three gen-
erations (Fig. 1a). Conversely, all four NODAL variants
were inherited from apparently unaffected parents; this is
consistent with incomplete penetrance of these pathogenic
variants, which is well-described for pathogenic variants in
this gene [17]. For example, in the one available NODAL
multiplex pedigree, a splice variant in patient LAT0022 was
shown to be inherited from an apparently unaffected father
and was shared with an affected paternal aunt (Fig. 1b).
Somewhat surprisingly, three of the four predicted-
damaging SNVs in NODAL were predicted loss-of-
function variants—an uncommon observation in this gene
(pLI= 0.95 [18]). We also observed compound hetero-
zygous, rare, predicted-damaging SNVs in five genes pre-
viously implicated in either PCD—DNAI1, DNAH5,
DNAH11, and HYDIN (1 case each), or HTX - MMP21 (2
cases), PKD1L1. PCD was not a part of the study entry
criteria, and none of the cases harboring variants in PCD
genes were known to have PCD. A genetic and phenotypic
overlap between PCD and laterality has been previously
postulated [19] and our data support this. Homozygous and
compound heterozygous variants in MMP21 have been
reported as the cause of HTX in a total of 14 cases (from 12
families) [20, 21]. Our recent report of homozygous
recessive PKD1L1 variants as a cause of HTX included
both the case reported here and another case with a
homozygous splicing variant in PKD1L1 [22]. Amongst
known laterality genes, the largest contribution of predicted-
damaging SNVs was in ZIC3—we observed five LOF
SNVs (5 cases) and one predicted-damaging missense
variant (1 case), including pathogenic variants in three cases
that we have previously reported [10]. Consistent with X-
linked disease inheritance, ZIC3 candidate variants were all
found in the hemizygous state in male offspring and were
inherited from heterozygous mothers, with evidence of
more extensive X-linked segregation of the phenotype in
available pedigrees (Fig. 1c and ref. [10]).
Novel human laterality candidate genes
Finding likely pathogenic variants in known laterality genes
served as a benchmark for our a priori filtering approach.
Next, we focused on candidate laterality variation in genes
not previously implicated in human disease. De novo var-
iants have been shown to be of particular relevance in CHD
[23–26]; however, we did not observe any of the candidate
variants in our cohort to occur de novo. We observed rare
heterozygous singleton LOF SNVs in six candidate genes
with strong supporting evidence for a role in cardiac
development and a low tolerance for loss-of function var-
iation (pLI) in gnomAD—SMAD2, ROCK2, ISL1, and
SUPT16H (Table 1). Where parents and family members
were available to assess segregation, these variants, with the
exception of SUPT16H but like those in NODAL, all
showed evidence of dominant inheritance with incomplete
penetrance—all were transmitted from parents without a
reported history of significant cardiac disease. De novo
damaging variants in SMAD2 were previously reported in
two cases from a large genetic study of CHD [23, 24],
which, on review, both had phenotypes consistent with
laterality. In our cohort, the SMAD2 LOF variant was
inherited from an unaffected father whose brother passed
away with a diagnosis of HTX prior to genetic testing
(Fig. 1d).
We did not systematically perform echocardiograms or
additional molecular (e.g., mosaicism) investigations on
carrier parents; therefore, reportedly ‘unaffected’ parents
could still have less severe, undetected, laterality pheno-
types. Given the known incomplete penetrance of dominant
inherited variants in these disorders [25], the predicted
molecular effect of the identified variants on the protein,
and robust prior biological support, we chose to maintain
these presumed partially penetrant dominant genes on our
candidate list.
We observed biallelic, rare, predicted-damaging variants
occurring in trans in one gene not previously associated
with either PCD or laterality defects in humans- ZFYVE16
(Table 1). ZFYVE16 encodes a FYVE zinc finger domain
protein; related proteins in this family have been implicated
in TGF-β and BMP signaling through Smads [27], as well
as in ventral folding of the developing mouse embryo,
including heart development [28]. Notably, these ZFYVE16
variants were observed in the same male individual with a
hemizygous frameshift variant in ZIC3 (LAT0264—see
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Table 1). In addition to Dextrocardia, this individual was
also noted to have an absent stomach; an unusual feature
suggestive of a more severe phenotype outside of the true
laterality spectrum.
We also assessed evidence for X-linked inheritance
models among our candidate genes. We noted a male pro-
band with a hemizygous, maternally-inherited RAI2 variant
and SIT in combination with asplenia as well as other
cardiac and vascular abnormalities (Table 1; Supplementary
Table S5). RAI2 (retinoic-acid induced 2) encodes a protein
(RAI2) of unclear function that is thought to regulate
transcription. RAI2 is expressed in fetal heart, brain, and
kidney [29], and copy number loss of chromosome Xp22,
encompassing RAI2, has been noted in two families with a
syndromic diagnosis that included congenital heart lesions
[30]. Another retinoic-acid induced gene—RAI1 —is
the putative phenotypic driver in Smith–Magenis syndrome
(MIM# 182290), a neurodevelopmental syndrome
that includes cardiac defects and is caused by hap-
loinsufficiency of 17p11.2 due to deletion CNV or LOF
SNV in RAI1.
Homozygous and Hemizygous exon deletions in
human laterality disorders
Next, we assessed structural genomic variation in our
cohort; specifically, small and rare hemizygous and homo-
zygous deletions detectable from comparison of whole
exome sequence reads [31]. We observed a total of 14 high-
confidence events (Z <−1.5 (autosomes), Z <−1.0 (X
chromosome); maximum 3 events per person and 3 over-
lapping event calls) (Supplementary Table S6). One of these
events overlapped our original a priori list - a hemizygous
single exon deletion of ZIC3 observed in a patient with a
common AV canal, asplenia, single ventricle, and atrio-
ventricular valve regurgitation. Subsequent validation and
parental testing showed this deletion to be maternally
inherited (Fig. 2). We also validated an inherited, hemi-
zygous single exon deletion of RIPPLY1 (Ripply Tran-
scriptional Repressor 1) in a male patient with abdominal
situs inversus, asplenia, interrupted inferior vena cava
(IIVC), total anomalous pulmonary venous return (TAPVR)
and complex CHD (D-TGA, common AV canal, ventricular
septal defect, atrial septal defect, pulmonary atresia) (Sup-
plementary Figure F1). Although not on our original a priori
list, RIPPLY1 encodes a putative transcriptional repressor
that acts in the NOTCH pathway and is paralogous to
RIPPLY2, which we have recently described in a case of
autosomal recessive Klippel-Feil syndrome with SIT [32].
In zebrafish embryos, Ripply1 interacts with Tbx6 and
Mesp-b to regulate somite and vertebral development [33],
and t-box genes are known to be important regulators of the
establishment of asymmetry mediated by cilia in Kupffer’sTa
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vesicle [34], making it a strong candidate gene for laterality
defects.
Possible multigenic contribution to human laterality
disorders
Recent studies have revealed associations between common
variants and a variety of cardiovascular traits [35, 36], as
well as highlighting the complex multigene/multi-variant
interactions in hypoplastic left heart syndrome [37].
Therefore, we chose to expand our interrogation
beyond single marker Mendelian analyses to perform gene-
based aggregation analyses across the entire exome by
comparing the burden of putative loss-of-function and
predicted-damaging nonsynonymous variation between
laterality cases and ARIC controls (see Methods). This
analysis revealed compelling statistical evidence (surpass-
ing our significance threshold of p < 7.06 × 10−6) for two
genes—PXDNL and BMS1 (Supplementary Table S7), with
little evidence of systematic stratification between the
cohorts.
Although neither Peroxidasin-like (PXDNL;
p= 1.61 × 10−6) or Ribosomal biogenesis factor (BMS1;
p= 7.29 × 10−7) were included on our a priori list, both
are good biological candidates in the context of the
broader laterality phenotype. PXDNL is a homolog of
human peroxidase that is exclusively expressed by car-
diomyocytes in the human heart and thought to interact
with peroxidase in remodeling of the extracellular matrix
after stress exposure [38]. BMS1 is highly conserved
across species. The zebrafish homolog, bms1l, is strongly
expressed throughout the digestive tract and accessory
organs including the liver, and mutant bmsl1 has
been associated with hypoplasia of the liver and
digestive tract [39]. Thus, BMS1 may be of particular
relevance to the ~2/3rds of our cohort with extra-cardiac
laterality defects, which included liver abnormalities and
intestinal malrotation (Supplementary Tables S2 and
S5), as was evident in two of the six LOF variant
carriers.
Discussion
Our analysis of rare damaging variation and exonic dele-
tions with suspected and established CHD genes detected
Fig. 1 Multiplex families with
laterality defects and CHD.
Families segregating variants in
ACVR2B (a, dominant), NODAL
(b, dominant), ZIC3 (c, X-
linked), and SMAD2 (d,
dominant) are shown. Shaded
individuals are affected with a
laterality defect. Presence (+) or
absence (−) of variant is
indicated for tested individuals.
Accompanying numbers
indicate LAT IDS (see
Supplementary Table S2).
Phenotypes are provided for
affected individuals for whom a
DNA sample was not available
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28 compelling monogenic candidate variants (26 SNV/
indels, 2 deletion CNV) in 25 of 323 cases, or 7.1% of our
starting cohort of unrelated laterality patients. This approach
identified pathogenic and likely pathogenic variants in
known and putative laterality genes, expanding the spec-
trum of disease-causing variation within these genes.
Though we incorporated evidence from familial segregation
patterns of these variants when possible, these variants were
not primarily ascertained using family-based methods. This
demonstrates that stringent variant filtering strategies can be
used to identify candidate variants in rare disease case
cohorts without the necessity of performing WES in all
family members. Nevertheless, the overall “solve” rate
would likely improve using a combination of these
approaches.
We anticipate that further genetic studies of this pheno-
type will confirm many of our candidates and identify new
ones, thereby improving the overall molecular diagnostic
rate for laterality defects. For instance, our approach was
able to confirm SMAD2 (dominant) as a laterality CHD
gene alongside two reported de novo cases identified from
large CHD cohorts [23, 24], and was instrumental in iden-
tifying and confirming PKD1L1 (recessive) [22]. We thus
posit RIPPLY1 (X-linked hemizygous) and RAI2 (two X-
linked hemizygous cases) as particularly compelling later-
ality candidates emerging from our analyses.
The majority of cases remained without an identifiable
genetic etiology. In part, this reflects the limitations of our
somewhat conservative analytical framework—we restric-
ted our Mendelian SNV analyses to high-confidence bio-
logical candidates and imposed a high threshold for
pathogenic variant classification among identified variants.
This enabled us to bring our analytical framework in line
with recent recommendations for inferring pathogenic and
likely-pathogenic genomic variants [40]—the variants in
newly described candidate genes presented here would be
considered to have (at least) moderate evidence of patho-
genicity. Nevertheless, our stringent criteria and cohort
approach could miss potential pathology-contributing var-
iants in individual patients and families. Future surveys that
incorporate data from the entire exome/genome, utilize
segregation in larger pedigrees, and prioritize functional
validation of novel variation will be of high value in further
expanding the genetic spectrum of these defects.
The variants and candidate genes we identified in indi-
vidual subjects suggest that alleles contributing to laterality-
Fig. 2 Hemizygous partial deletions of ZIC3. a WES read count data
(RPKM) plotted for subject LAT0097 (red line) and all other BHCMG
subjects (black lines) in the indicated regions of the X chromosome.
Near-zero RPKM values in (a) suggest a hemizygous deletion of the
final exon of ZIC3; b Confirmation and mapping of ZIC3 CNV by
array comparative genomic hybridization using a custom 8 × 60k
probe Agilent array (design ID= 064211). This array and all array
procedures have been described previously [49]. c To more accurately
map the CNV, long-range PCR with primers spanning the predicted
breakpoints was employed, resulting in a smaller product compared to
wild-type (ctrl DNA); sequencing of the resulting PCR product illu-
strated the deleted region (d)
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related traits largely segregate with either recessive or X-
linked inheritance, although we did observe suggestive
examples of dominant and complex/polygenic modes of
inheritance. Almost all of the dominant heterozygous LOF
variants we observed—both in known and new candidate
genes—were inherited from apparently unaffected parents.
With new candidate genes, it is difficult to know a priori
whether haploinsufficiency is sufficient to cause disease;
however, this phenomenon is consistently observed in
known laterality-causing genes such as NODAL, and was
congruent with the disease segregation of SMAD2 LOF
variants in extended families. One potential mechanism
contributing to this observation is parental mosaicism. We
did not perform WES on parents, and although validation
traces were not highly suggestive of mosaicism, a role for
low-level gonadal- or germline- mosaicism cannot be
completely ruled out. Another consideration is that the
phenotype of dominantly-inherited laterality genes may
involve more complex mechanisms of non-penetrance [37]
and variable expressivity [41], such that ‘unaffected’ carrier
parents might have milder phenotypes that do not readily
come to clinical attention. It may also be that multiple ‘hits’
are required to disturb the complex processes involved in
early embryonic left-right patterning, such that the effect of
a single heterozygous ‘hit’ is most relevant in the context of
epistatic modifiers around the genome [42]. Similarly,
multi-locus variation may provide an adverse variant burden
in a pathway, system or interactome [43]. The latter two
speculations are bolstered by the associations between the
burden of rare variation in BCL1 and PDXNL and laterality
defects. A similar argument can be made for rare compound
heterozygous damaging variants in ZFYVE16 occurring in
the same individual (LAT0264) carrying a ZIC3 frameshift
variant (Table 1). Functional studies of our candidate var-
iants in model organisms together with consideration of
more complex multi-locus genetic models may help to
confirm or refute these notions.
Expanded assessments of coding-sequence variation,
however, may leave our understanding of the etiology of
laterality defects incomplete. For instance, LOF variants
accounted for all but one of the ZIC3 variants, and included
distinct types of LOF variants (LAT0180—frameshift;
LAT1177—stopgain; LAT0097—hemizygous deletion).
The effects of these variants converge on absence of ZIC3
protein; thus, it may follow that other variants with a similar
effect could also cause HTX and congenital heart disease
(e.g., miRNA, gene silencer motifs). Screening for these
and other categories of LOF-like variation in ZIC3 could be
prioritized in future genomic analyses of HTX, in addition
to the exome-centric analyses presented here.
This study provides a comprehensive coding-sequence
survey for variants at known and putative candidate loci in
laterality defects. The results implicate a total of six
candidate genes for human laterality defects and reinforce
that the genetic architecture of such defects is complex,
spanning several single gene inheritance models, potential
multi-locus contributions and other putative disease
mechanisms. These data provide a basis for future investi-
gation of additional monogenic causes of heterotaxy and
related defects in left-right patterning as well as a starting
point for discovery of complex genetic mechanisms
underlying CHD and other human birth defects.
Methods
Case ascertainment
Cases were recruited through Texas Children’s Hospital
(TCH) in Houston, TX. The Institutional Review Board of
Baylor College of Medicine approved the study and all
participating subjects gave informed consent. When avail-
able, parents and affected family members of the index
cases were also invited to participate. The details of case
ascertainment have been previously published [17]; briefly,
patients were eligible if they presented with evidence of
disturbed left-right patterning, which included situs
abnormalities (SIT, HTX) or an isolated congenital mal-
formation consistent with disturbed left-right patterning
such as D-TGA or DORV (summarized in Supplementary
Table S2). The clinical diagnoses were confirmed by a
detailed review of medical records, including radiologic and
cardiac-specific imaging. DNA samples were obtained from
blood, saliva, and skin fibroblasts as previously described
[17].
Cardiovascular gene set
Given the strong relationship between laterality and CHD,
we compiled a list of 1702 human genes with a priori evi-
dence for a role in laterality and/or cardiovascular mal-
formation (CVM) from multiple public resources
(Supplementary Table S3). This list was compiled from
searches of human disorders including laterality defects and
CVM (OMIM, NCBI, literature), relevant biological path-
ways and interactions (HH, NOTCH, TGFβ, PITX2) as
determined by the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database, and model organism support
including zebrafish heart expression (ZFIN) and abnormal
cardiac morphology in mouse models (MGI, MP:0000266).
Population-based allele frequency comparison
In additional to population-based databases of variant minor
allele frequencies—Exome Aggregation Consortium
(ExAC, v 0.3.1), Genome Aggregation Database (gnomAD,
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v3.0.1), Exome Variant Server (EVS)—WES data from
5492 European American (EA) individuals from the
population-based Atherosclerosis Risk in Communities
(ARIC) study—sequenced and annotated using the same
pipeline as the laterality cases [44]—were utilized as a
variant frequency comparison group. ARIC samples with
heart failure, major Q-wave, or LVH by the Cornell defi-
nition were excluded from the analyses.
Whole exome sequencing, annotation, and
validation
WES was performed on 323 individual cases at the Human
Genome Sequencing Center at Baylor College of Medicine
through the Baylor-Hopkins Center for Mendelian Geno-
mics initiative using the Illumina HiSeq platform and the
Mercury pipeline [45]. ARIC samples were captured using
VCRome 2.1 (42Mb) and HTX cases were captured using
HGSC-CORE (52Mb), and all analyses were restricted to
the intersection of the targeted regions of these reagents.
Furthermore, we analyzed only high-quality genotypes
including single base substitutions with a minimum cover-
age of 10x, and small insertions/deletions (indels) with
>30x coverage. Read mapping to Genome Reference
Consortium Human Build 37 (GRCh37) was performed
with Burrows-Wheeler alignment [46], and allele calling
was performed with the Atlas2 suite [47] (Atlas-SNP, Atlas-
Indel) in order to identify high-quality variants annotated
for their potential protein-damaging effect. All candidate
SNVs from the laterality cohort were validated on an
orthogonal platform (Dideoxy -Sanger- sequencing) in
cases. In order to assess inheritance patterns, validated
variants were then genotyped, using the same methodology
(dideoxy -Sanger- sequencing), in parents and available
family members.
Variant filtering
The Variant Call File (VCF) contained flagged low-quality
variants including SNPs with posterior probability lower
than 0.95, total depth of coverage less than 10x, fewer than
3 variant reads, an allelic fraction less than 10%, 99% reads
in a single direction, and homozygous reference alleles with
< 6x coverage. We increased stringency to remove low-
quality indels with a total depth less than 30x and allelic
fraction below 30%. Eight cases presented extremely high
or low heterozygosity (more than 3 standard deviations
from sample mean) and were excluded from burden ana-
lyses. Variants were annotated to Refseq gene definitions
using ANNOVAR. Conservative loss-of-function (LOF)
annotation was performed by selecting only included pre-
mature stopgains in the non-terminal exon, essential splice
sites used by all gene isoforms, and frameshift indels
similarly mapping to all isoforms. Damaging nonsynon-
ymous (DNS) variation was defined as protein-altering
substitutions predicted to be damaging by a consensus of at
least 3 out of 6 prediction scores downloaded via dbNSFP
(SIFT, Polyphen2 HDIV, LRT, Mutation Taster, Mutation
Assessor, FATHMM). A PHRED-like scaled C-score
(CADD) was also used to assess pathogenicity of variants
(LOF and DNS), but was not used to exclude candidate
sites. LOF constraint was quantified by first calculating the
sum of all LOF alleles in ARIC (gene-wise observed LOF).
Next, we simulated all potential nucleotide substitutions in
exonic regions to determine the number of total potential
LOF sites for each gene and calculated the ratio of observed
to potential LOF alleles (OP ratio). OP ratios were used
alongside pLI (probability of loss-of-function scores from
ExAC/gnomAD), to filter for genes with a very low OP
ratio (zero, or lowest 30th percentile) or high pLI score
(>0.9) amongst laterality candidates. Variants identified in
known laterality genes were also curated for pathogenicity
using ACMG/AMP criteria [48], and then annotated as
either a variant of uncertain significance (VUS), a likely
pathogenic (LP), likely benign (LB), or pathogenic (P)
variant (Table 1; Supplementary Table S8). Finally, for
large genes in which we observed singleton biallelic var-
iants in trans (e.g., DNAH5, DNAH11 and HYDIN), we also
calculated the chance of observing two such variants by
taking the maximum frequency of the two observed variants
and catalogued all other variants (in gnomAD) in the gene
at that frequency or lower. The resulting frequencies were
added, assuming independent segregation, to give the pro-
portion of people with rare variants. Assuming random
mating, we then estimated the chance that any two variants
would be observed in the same person. If this probability of
biallelic variants occurring by chance was higher than
observed in our cohort, we removed the gene in question
(e.g., DNAH11), keeping those that were less than
observed.
WES of laterality cases revealed 1,217,653 total variants
(1,152,651 single nucleotide substitutions, and 65,002 small
indels; Supplementary Table S4) across the entire allele
frequency spectrum.
Validation of hemizygous/homozygous copy losses
CNVs were confirmed and mapped by array comparative
genomic hybridization using a custom 8 × 60k probe Agi-
lent array (design ID= 064211). This array and all array
procedures have been described previously [49]. To more
accurately map the CNV and provide substrate for break-
point sequencing, long-range PCR with primers spanning
the predicted breakpoints was employed. PCR reagents and
concentrations have been described previously [50]. The
thermal cycler was programmed as follows: 94 °C x 1 min;
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30 cycles of 94 °C x 30 sec followed by 68 °C x 7 min; 72 °
C x 10 min. PCR primers are listed in the Supplemental
Methods. Breakpoint PCR products were treated with
ExoSAP-IT (Affymetrix) according to the manufacturer’s
instructions, then sequenced by Sanger di-deoxynucleotide
sequencing (Baylor College of Medicine Sequencing Core,
Houston, TX, USA).
Gene burden testing
Firth logistic regression was performed on case-control
status using the total number of heterozygous sites per
individual as a covariate in order to address potential plat-
form differences between sequencing batches. These ana-
lyses were restricted to samples of reported European
ancestry (111 HTX cases; 5,752 ARIC participants) and
excluded genes in the MHC region of chromosome 6 and
multiallelic variants. Only rare DNS/LOF variation that
were covered at 10x or better and meeting our variant-
filtering criteria in both cohorts were included in our ana-
lyses; a p-value of 7 × 10−6—reflecting a Bonferroni cor-
rection for 7086 genes harboring DNS in the case cohort –
was deemed statistically significant.
Web resources
1000 Genomes, http://browser.1000genomes.org
ExAC Browser, http://exac.broadinstitute.org/
gnomAD Browser, http://gnomad.broadinstitute.org/
dbNSFP, http://varianttools.sourceforge.net/Annotation/
DbNSFP
OMIM, http://www.omim.org/
UCSC Genome Browser, http://genome.ucsc.edu
HMZDelfinder, https://github.com/BCM-Lupskilab/
HMZDelFinder
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